Home » Articles » News

FDA approves Oyster Point's nasal spray for dry eye disease | Inquirer News...

FDA approves Oyster Point's nasal spray for dry eye disease | Inquirer News
"FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly
Drug developer Oyster Point Pharma Inc said on Monday the U.S. Food and Drug Administration had approved its nasal spray treatment for dry eye disease.
The company said the spray, Tyrvaya, will be available from next month to patients with a prescription.
ADVERTISEMENT

The regulator’s decision was based on safety and efficacy results from a late-stage and two mid-stage trials covering over 1,000 patients with mild, moderate or severe symptoms of dry eye disease (DED).
More than 30 million people in the United States are affected by the chronic condition characterized by stinging, sensitivity to light, blurred vision and eye fatigue.FEATURED STORIES
NEWSINFO
Roque bares Sara Duterte’s last-minute appeal for him to run for Senate

NEWSINFO
‘Saving’ Manila Bay: Dolomite beach, wetlands drowning in wastes

NEWSINFO
Bongbong, family attend China embassy’s photo wall ribbon-cutting event

Oyster Point in March said data from the trials showed that Tyrvaya demonstrated statistically significant improvement in production of tear film on eye surface in all trials.
Tear film helps to keep eyes moist, reducing risks of infection and contributing to clear vision.

Recommended videosPowered by AnyClip1/7North Korea says US overreacting over missile testRead More



7.8K



2





Video Player is loading.Play VideoUnmuteDuration /Current Time Playback Speed Settings1xLoaded: 0%Remaining Time - FullscreenPlayUp NextThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Playback Speed0.25x0.5x1x Normal1.5x2xReplay the listPowered by AnyClip Privacy Policy

TOP ARTICLES







































North Korea says US overreacting over missile test
NOW PLAYING
UP NEXT





Ethiopia hits Tigray's capital with third airstrike
NOW PLAYING
UP NEXT





Isko Moreno promises to cut tax on fuel, electricity by 50%
NOW PLAYING
UP NEXT





WATCH: OCEAN PARK SA MANILA, BUKAS NA | CHONA YU
NOW PLAYING
UP NEXT





WATCH: MGA MAGSASAKA, UMAARAY NA SA SMUGGLING NG GULAY NA GALING CHINA | CHONA YU
NOW PLAYING
UP NEXT





WATCH: MGA MAGSASAKA, SUMUGOD SA MENDIOLA | CHONA YU
NOW PLAYING
UP NEXT





Atienza: Makabayan endorses Pacquiao
NOW PLAYING
UP NEXT



North Korea says US overreacting over missile test





“A product that provides clinically meaningful production of basal tear film as early as four weeks is incredible for the dry eye patient,” Ed Holland, director of cornea services at Cincinnati Eye Institute and professor of ophthalmology at University of Cincinnati said in the company’s statement.
Tyrvaya is a nasal spray formulation of the drug varenicline, also used in Pfizer Inc’s smoking cessation drug, Chantix.
Tyrvaya works by activating a nerve that stimulates natural tear film production, and in turn relieving symptoms of dry eye disease.
.inline_ffff input { width: 70%!important; }
.bypro {
float: right;
width: 71%;
text-align: center;
margin-top: -12px;
margin-right: 15px;
clear: both;
color: #5C5C5C;
font-size: 8px!important;
line-height: 9px!important;

}
.lfform-inquirer-horizontal h2 {
font-weight: bold !important;
font-family: mallory !important;
}
@media only screen and (min-width: 360px) and (max-width: 767px) {
.lfform-inquirer-horizontal #myForm3 {
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: center;
}
.lfform-inquirer img {
width: 100% !important;
margin: 0 !important;
}
.bypro {
margin-top: 10px;
}
.lfform-inquirer-horizontal input[type=""email""] {

width: 100% !important;
}
.lfform-inquirer-horizontal input[type=""submit""], .lfform-inquirer-horizontal input[type=""button""] {

width: 100% !important;
}
}

.formv4 {
width: 100%!important;
max-width: 100%;
margin: 15px 0;
}
.formv4 input[type=""email""] {
font-weight: bold;
float: left;
-webkit-appearance: none;
margin: 0!important;
width: 70% !important;
}
.formv4 input[type=""submit""] {
font-weight: bold;
width: 28% !important;
padding: 3%;
float: left;
-webkit-appearance: none;
}
.formv4 #myForm3 {
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: space-between;
}
.formv4 .bypro {
width:100%;
font-family: 'noto serif';
float: unset;
clear: both;
color: #333333;
font-size: 11px!important;

line-height: 1 !important;
margin: 10px 3px;
text-align:left;
}
.formv4 a, .formv4 a:visited, .formv4 a:hover {
color: #0b72b5 !important;
text-decoration: none; !important;
}

.formv4 h2 {
font-weight: bold !important;
text-align: left;
font-family: mallory !important;
color: #333333 !important;
margin:5px 0 !important;
padding: 0 !important;
}
.formv4 p {
width: 100%;
text-align: left;
color: #5A5A5A !important;
font-family: 'noto serif' !important;
font-size: 14px !important;
margin: 0 !important;
line-height: 1.6em !important;
margin-bottom: 15px !important;
padding: 0 !important;
}

@media only screen and (min-width: 360px) and (max-width: 767px) {
.formv4 h2 {

font-size: 16px !important;
}
.formv4 .bypro {
font-size: 12px!important;
margin: 5px 5px;
}
.formv4 input[type=""email""] {

width: 100% !important;
}
.formv4 input[type=""submit""] {
width: 100% !important;
margin: 10px 0;
}
.formv4 {
width: 95%!important;
max-width: 95%;
margin: 20px auto;
}
}

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

#inqplus-article2 {
width: 100%;
height: 250px;
margin: 20px auto;
background-color: #a5b8c5;
display: flex;
flex-wrap: wrap;
justify-content: space-between;
align-items: flex-start;
}
#inqplus-cta-wrap {
width: 50%;
height: 250px;
background-image: url(/single2017/images/inqplus-sub/inqplus-cta-bg1.png);
background-repeat: no-repeat;
background-size: cover;
}
#inqplus-cta2 {
width: 89%;
height: auto;
margin: 35px auto 0;
}
#inqplus-cta2 img {
width: 100%;
}
#newsletter-cta-wrap {
width: 50%;
height: 250px;
background-image: url(/single2017/images/inqplus-sub/newsletter-bg1.png);
position: relative;
background-repeat: no-repeat;
background-size: cover;
}
#newsletter-cta2 {
width: 95%;
position: absolute;
bottom: -4px;
z-index: 1;
}
#newsletter-cta2 img {
width: 100%;
}
#inqplus-nl-sub2 {
width: 65%!important;
display: flex;
font-size: 0;
box-sizing: border-box;
z-index: 2;
position: absolute;
bottom: 10px;
right: 10px;
}
#inqplus-nl-sub2 form {
width: 100%!important;
}
.sub-input2 {
width: 70%!important;
height: 25px!important;
border: 0!important;
padding: 5px 0 5px 10px!important;
margin: 0!important;
box-sizing: border-box!important;
border-radius:0;
-webkit-appearance:none;
}
.sub-btn2 {
width: 30%!important;
height: 25px!important;
border: 0!important;
padding: 0!important;
margin: 0!important;
background-color: #004a87!important;
color: #f5f5f5!important;
text-transform: uppercase!important;
border-radius:0;
-webkit-appearance:none;
}
/* 414px */
@media only screen and (min-width: 414px) and (max-width: 599px){
#inqplus-article2 {
width: 98%;
height: auto;
}

#inqplus-cta-wrap {
width: 100%;
height: auto;
}

#newsletter-cta-wrap {
width: 100%;
}

#newsletter-cta2 img {
width: 90%;
}

}

/* 320px */
@media only screen and (min-width: 320px) and (max-width: 413px){
#inqplus-article2 {
width: 98%;
height: auto;
}

#inqplus-cta-wrap {
width: 100%;
}

#newsletter-cta-wrap {
width: 100%;
}

}

Read Next

Over 9K repatriated Filipinos arrive via Subic airport since July

VerrulonRemove Warts & Skin Tags Safely At Home! Try Out Now!Verrulon|SponsoredSponsoredUndoAcuStepsAng simpleng pamamaraan na ito ay aalisin ang sakit ng buong katawan. Subukan ito ngayong gabi!AcuSteps|SponsoredSponsoredUndoTips and TricksA Marine rushes home to greet his wife, but is surprised when he sees her.Tips and Tricks|SponsoredSponsoredUndoPerfect-Dating.comAgusan Del Norte is actually full of single handsome guys. Check them out on this free dating sitePerfect-Dating.com|SponsoredSponsoredUndoStudent SeaKate Middleton's Daring Outfit Took Prince William's Breath AwayStudent Sea|SponsoredSponsoredUndoTips and Tricks[Gallery] Teenage pole vaulter's life is almost ruined after pictures go viralTips and Tricks|SponsoredSponsoredUndoBETER - leading providerSports betting odds, api for sportsbooksBETER - leading provider|SponsoredSponsoredUndo

window._taboola = window._taboola || [];
_taboola.push({
mode: 'thumbnails-d',
container: 'taboola-below-article-thumbnails-desktop',
placement: 'Below Article Thumbnails - newsinfo',
target_type: 'mix'
});


window._taboola = window._taboola || [];
_taboola.push({
mode: 'thumbnails-e',
container: 'taboola-below-article-thumbnails-mobile',
placement: 'Below Article Thumbnails - newsinfo',
target_type: 'mix'
});

EDITORS' PICK

Delivering delight against all odds

Next level mobile photography within reach with vivo X70 co-engineered with ZEISS

Leaked: A 60x Zoom and all-new Helio G96 mean a complete overhaul for TECNO Mobile’s new CAMON 18 series

PNP urges public: Do your part, follow safety protocols while on holidays

Manila Ocean Park reopens to public

Malls, parks in NCR still off limits to minors even with eased restrictions

MOST READ

Robredo to supporters: Be calm, gentle and do good deeds

Drilon: Tax and then ban Chinese firm in pandemic funds mess

AJ Raval apologizes to Kylie for posting Aljur’s ‘breaking silence’ statement, takes ‘social media detox’

‘Saving’ Manila Bay: Dolomite beach, wetlands drowning in wastes

Don't miss out on the latest news and information.

View comments"
 

Please support us in writing articles like this by sharing this post

Share this post to your Facebook, Twitter, Blog, or any social media site. In this way, we will be motivated to write articles you like.

--- NOTICE ---
If you want to use this article or any of the content of this website, please credit our website (www.affordablecebu.com) and mention the source link (URL) of the content, images, videos or other media of our website.

"FDA approves Oyster Point's nasal spray for dry eye disease | Inquirer News" was written by Mary under the News category. It has been read 48 times and generated 0 comments. The article was created on and updated on 17 November 2021.
Total comments : 0